berberine has been researched along with Cardiovascular Diseases in 34 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine has been widely used for the adjuvant therapy of several cardiovascular diseases (CVDs)." | 9.41 | Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. ( Shen, T; Wu, W; Yang, L; Zhang, X; Zhou, X; Zhu, W, 2023) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 7.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 6.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| "In conclusion, this study demonstrates that the combination of monacolin K, berberine and coenzyme Q10 is effective and safe for treating hypercholesterolemia in patients with a moderate degree of excess LDL-C and cardiovascular risk." | 5.51 | Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk. ( Arnás, C; Corbella, E; de Dios, S; Florido, M; Licerán, M; Martin, D; Martinez-Martin, F; Petitbò, D; Pintó, X; Sánchez, A; Sánchez-Hernández, RM; Sarasa, I; Trias, F, 2022) |
| " Lycopene and berberine are natural plants with a wide range of beneficial effects including protective activities against metabolic disorders such as diabetes and cardiovascular diseases." | 5.12 | Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. ( Hedayati, N; Naeini, MB; Oskouei, Z; Tabeshpour, J, 2021) |
| " Among these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood." | 4.91 | Potential benefits of berberine in the management of perimenopausal syndrome. ( Caliceti, C; Cicero, AF; Rizzo, P, 2015) |
| "The previous work has shown that Berberine and Hesperidin have beneficial effects on cardiovascular diseases." | 3.91 | The protective effects of Berberine and Hesperidin on inflammatory factor-stimulating cardiac fibroblasts. ( Dai, FY; Li, P; Wang, YF; Yu, XH; Zhao, JH, 2019) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 3.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| "Berberine, as an alkaloid found in many Chinese herbs, improves vascular functions in patients with cardiovascular diseases." | 3.81 | Berberine via suppression of transient receptor potential vanilloid 4 channel improves vascular stiffness in mice. ( Guo, T; Peng, QS; Wang, J; Wang, SX; Yue, SW, 2015) |
| "Berberine was administered on them postoperatively." | 2.87 | Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy. ( Dong, X; Hongli, L; Qing, Y; Yanhui, L, 2018) |
| "Berberine and placebo were then interrupted for 2 months (washout period), and all patients continued with only diet and physical activity." | 2.78 | Effects of berberine on lipid profile in subjects with low cardiovascular risk. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D, 2013) |
| "The women were randomized to treatment with a nutraceuticals containing soy isoflavones (60 mg) and berberine (500 mg) or a placebo at a dosage of one tablet daily between meals for 12 weeks." | 2.78 | Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers. ( Borghi, C; Cicero, AF; De Sando, V; Ferroni, A; Grandi, E; Tartagni, E, 2013) |
| "Berberine is an alkaloid from several medicinal plants originally used to treat diarrhea and dysentery as a traditional Chinese herbal medicine." | 2.72 | Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. ( Cao, RY; Cao, W; Gu, W; Jiang, L; Li, Q; Sun, W; Yang, J; Zhang, Y; Zheng, H; Zheng, Y; Zhou, L, 2021) |
| "Berberine is a plant metabolite belonging to the group of isoquinoline alkaloids with strong biological and pharmacological activity." | 2.66 | Biological Activity of Berberine-A Summary Update. ( Nowak, R; Och, A; Podgórski, R, 2020) |
| " However, we also (b) observe that the plasma concentration of coptisine demonstrates obvious non-liner relationship with dosage, and even the highest dosage used in animal study actually cannot reach the minimum concentration level used in cell experiments owing to the poor absorption and low availability of coptisine." | 2.61 | Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review. ( Deng, D; Hu, Y; Li, S; Luo, Y; Meng, X; Su, S; Wang, P; Wu, J; Xiang, L, 2019) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 2.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| "Berberine is an alkaloid that is highly concentrated in the roots, rhizomes, and stem bark of various plants." | 2.48 | Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. ( Cicero, AF; Tartagni, E, 2012) |
| "Berberine is a isoquinoline alkaloid extracted from Chinese herbs such as Coptidis rhizome." | 2.44 | [Advances in the study of berberine and its derivatives]. ( Chen, KX; Li, B; Zhu, WL, 2008) |
| "Jatrorrhizine (Jat) is an effective component of Rhizoma Coptidis." | 1.91 | Jatrorrhizine inhibits Piezo1 activation and reduces vascular inflammation in endothelial cells. ( Hong, T; Li, J; Pan, X; Wen, L; Xia, M; Xu, H; Zheng, Z, 2023) |
| "Berberine has received rising attention for its application in cardiovascular disease because of its relationship with inflammation." | 1.72 | Berberine alleviates NLRP3 inflammasome induced endothelial junction dysfunction through Ca ( Chen, Q; Chen, Y; Dai, L; Huang, Y; Li, J; Liu, J; Luo, Y; Ma, S; Wang, L; Zhang, M; Zhou, X; Zhu, L, 2022) |
| "Berberine is an isoquinoline alkaloid present in several plant species, including Coptis sp." | 1.40 | Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. ( Chen, C; Fichna, J; Li, Y; Storr, M; Yu, Z, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 13 (38.24) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, RY | 1 |
| Zheng, Y | 1 |
| Zhang, Y | 1 |
| Jiang, L | 1 |
| Li, Q | 1 |
| Sun, W | 1 |
| Gu, W | 1 |
| Cao, W | 1 |
| Zhou, L | 1 |
| Zheng, H | 1 |
| Yang, J | 1 |
| Hedayati, N | 1 |
| Oskouei, Z | 1 |
| Tabeshpour, J | 1 |
| Naeini, MB | 1 |
| Dai, L | 1 |
| Zhu, L | 1 |
| Ma, S | 1 |
| Liu, J | 1 |
| Zhang, M | 1 |
| Li, J | 2 |
| Luo, Y | 2 |
| Zhou, X | 2 |
| Chen, Q | 1 |
| Wang, L | 1 |
| Huang, Y | 1 |
| Chen, Y | 1 |
| Martinez-Martin, F | 1 |
| Corbella, E | 1 |
| Sarasa, I | 1 |
| Trias, F | 1 |
| Petitbò, D | 1 |
| Licerán, M | 1 |
| Sánchez-Hernández, RM | 1 |
| Martin, D | 1 |
| Sánchez, A | 1 |
| Arnás, C | 1 |
| de Dios, S | 1 |
| Florido, M | 1 |
| Pintó, X | 1 |
| Fernández-Fernández, FJ | 1 |
| Sardina-Ferreiro, R | 1 |
| Ameneiros-Lago, E | 1 |
| Ye, Z | 2 |
| Wang, Q | 2 |
| Dai, S | 2 |
| Ji, X | 2 |
| Cao, P | 2 |
| Xu, C | 2 |
| Bao, G | 2 |
| Yang, L | 1 |
| Zhu, W | 1 |
| Zhang, X | 1 |
| Wu, W | 1 |
| Shen, T | 1 |
| Zhao, J | 1 |
| Ip, DKM | 1 |
| Leung, JYY | 1 |
| Vackova, D | 1 |
| He, X | 1 |
| Schooling, CM | 1 |
| Hong, T | 1 |
| Pan, X | 1 |
| Xu, H | 1 |
| Zheng, Z | 1 |
| Wen, L | 1 |
| Xia, M | 1 |
| Bellavite, P | 1 |
| Fazio, S | 1 |
| Affuso, F | 1 |
| Wu, J | 1 |
| Deng, D | 1 |
| Su, S | 1 |
| Li, S | 1 |
| Xiang, L | 1 |
| Hu, Y | 1 |
| Wang, P | 1 |
| Meng, X | 1 |
| Kwon, S | 1 |
| Chan, AT | 1 |
| Och, A | 1 |
| Podgórski, R | 1 |
| Nowak, R | 1 |
| Carrizzo, A | 1 |
| Izzo, C | 1 |
| Forte, M | 1 |
| Sommella, E | 1 |
| Di Pietro, P | 1 |
| Venturini, E | 1 |
| Ciccarelli, M | 1 |
| Galasso, G | 1 |
| Rubattu, S | 1 |
| Campiglia, P | 1 |
| Sciarretta, S | 1 |
| Frati, G | 1 |
| Vecchione, C | 1 |
| McCubrey, JA | 2 |
| Lertpiriyapong, K | 2 |
| Steelman, LS | 2 |
| Abrams, SL | 2 |
| Cocco, L | 2 |
| Ratti, S | 2 |
| Martelli, AM | 2 |
| Candido, S | 2 |
| Libra, M | 2 |
| Montalto, G | 2 |
| Cervello, M | 2 |
| Gizak, A | 2 |
| Rakus, D | 2 |
| Murata, RM | 1 |
| Rosalen, PL | 1 |
| Lombardi, P | 1 |
| Bianconi, V | 1 |
| Mannarino, MR | 1 |
| Sahebkar, A | 1 |
| Cosentino, T | 1 |
| Pirro, M | 1 |
| Qing, Y | 1 |
| Dong, X | 1 |
| Hongli, L | 1 |
| Yanhui, L | 1 |
| Feng, X | 1 |
| Sureda, A | 1 |
| Jafari, S | 1 |
| Memariani, Z | 1 |
| Tewari, D | 1 |
| Annunziata, G | 1 |
| Barrea, L | 1 |
| Hassan, STS | 1 |
| Šmejkal, K | 1 |
| Malaník, M | 1 |
| Sychrová, A | 1 |
| Barreca, D | 1 |
| Ziberna, L | 1 |
| Mahomoodally, MF | 1 |
| Zengin, G | 1 |
| Xu, S | 1 |
| Nabavi, SM | 1 |
| Shen, AZ | 1 |
| Guo, HH | 1 |
| Feng, CL | 1 |
| Zhang, WX | 1 |
| Luo, ZG | 1 |
| Zhang, HJ | 1 |
| Zhang, TT | 1 |
| Ma, C | 1 |
| Zhan, Y | 1 |
| Li, R | 1 |
| Wu, S | 1 |
| Abliz, Z | 1 |
| Li, C | 1 |
| Li, XL | 1 |
| Ma, XL | 1 |
| Wang, LL | 1 |
| Zheng, WS | 1 |
| Han, YX | 1 |
| Jiang, JD | 1 |
| Yu, XH | 1 |
| Wang, YF | 1 |
| Dai, FY | 1 |
| Zhao, JH | 1 |
| Li, P | 2 |
| Derosa, G | 1 |
| D'Angelo, A | 1 |
| Bonaventura, A | 1 |
| Bianchi, L | 1 |
| Romano, D | 1 |
| Maffioli, P | 1 |
| Cicero, AF | 5 |
| Tartagni, E | 3 |
| Ertek, S | 1 |
| Reggi, A | 1 |
| Parini, A | 1 |
| Morbini, M | 1 |
| Rosticci, M | 1 |
| Grandi, E | 2 |
| Borghi, C | 2 |
| Chen, C | 1 |
| Yu, Z | 1 |
| Li, Y | 1 |
| Fichna, J | 1 |
| Storr, M | 1 |
| Liu, C | 1 |
| Wang, Z | 1 |
| Song, Y | 1 |
| Wu, D | 1 |
| Zheng, X | 1 |
| Jin, J | 1 |
| Xu, N | 1 |
| Li, L | 1 |
| Caliceti, C | 1 |
| Rizzo, P | 1 |
| Wang, J | 1 |
| Guo, T | 1 |
| Peng, QS | 1 |
| Yue, SW | 1 |
| Wang, SX | 1 |
| Mazza, A | 1 |
| Lenti, S | 1 |
| Schiavon, L | 1 |
| Zuin, M | 1 |
| D'Avino, M | 1 |
| Ramazzina, E | 1 |
| Casiglia, E | 1 |
| McCarty, MF | 1 |
| O'Keefe, JH | 1 |
| DiNicolantonio, JJ | 1 |
| Li, B | 1 |
| Zhu, WL | 1 |
| Chen, KX | 1 |
| Fan, FL | 1 |
| Dart, AM | 1 |
| Ferroni, A | 1 |
| De Sando, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS in Metabolic Syndrome[NCT02912325] | 34 participants (Actual) | Interventional | 2017-05-09 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for berberine and Cardiovascular Diseases
| Article | Year |
|---|---|
Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action.
Topics: Berberine; Cardiovascular Diseases; Humans; Medicine, Chinese Traditional; Molecular Structure | 2021 |
Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review.
Topics: Berberine; Biological Availability; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mel | 2021 |
Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.
Topics: Berberine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Humans; | 2023 |
A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention.
Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; | 2023 |
Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antinematodal Agents; Autophagy; Berberine; Biologi | 2019 |
Biological Activity of Berberine-A Summary Update.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Berberine; Cardiovascular Diseases; Drug R | 2020 |
A Novel Promising Frontier for Human Health: The Beneficial Effects of Nutraceuticals in Cardiovascular Diseases.
Topics: Berberine; Biological Products; Brassica; Cardiovascular Diseases; Curcumin; Dietary Supplements; He | 2020 |
Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases.
Topics: Berberine; Cardiovascular Diseases; Curcumin; Gene Expression Regulation; Glycogen Synthase Kinase 3 | 2017 |
Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cardiovascular Diseases; Cholesterol; Curc | 2018 |
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.
Topics: Animals; Berberine; Cardiovascular Diseases; Cardiovascular System; Humans; Metabolic Diseases | 2019 |
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
Topics: Animals; Berberine; Body Weight; Cardiovascular Diseases; Cinnamomum zeylanicum; Dietary Supplements | 2014 |
Potential benefits of berberine in the management of perimenopausal syndrome.
Topics: Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; L | 2015 |
Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health.
Topics: Berberine; Biological Products; Cardiovascular Diseases; Clinical Trials as Topic; Diet Therapy; Hum | 2015 |
[Advances in the study of berberine and its derivatives].
Topics: Alzheimer Disease; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Be | 2008 |
Antidiabetic properties of berberine: from cellular pharmacology to clinical effects.
Topics: Animals; Berberine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2012 |
6 trials available for berberine and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk.
Topics: Berberine; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Heart Disease Risk Factor | 2022 |
Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy.
Topics: Aged; Autophagy; Berberine; Cardiotonic Agents; Cardiovascular Diseases; Cell Line; Female; Follow-U | 2018 |
Effects of berberine on lipid profile in subjects with low cardiovascular risk.
Topics: Adult; Anticholesteremic Agents; Berberine; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, | 2013 |
Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Berberine; Cardiovascular Diseases; Contraception; Contraceptives, | 2014 |
Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk.
Topics: Berberine; Biological Products; Blood Pressure; Cardiovascular Diseases; Diet; Dietary Supplements; | 2015 |
Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers.
Topics: Berberine; Biomarkers; Cardiovascular Diseases; Dietary Supplements; Female; Humans; Isoflavones; Li | 2013 |
13 other studies available for berberine and Cardiovascular Diseases
| Article | Year |
|---|---|
Berberine alleviates NLRP3 inflammasome induced endothelial junction dysfunction through Ca
Topics: Adenosine Triphosphate; Animals; Berberine; Calcium; Cardiovascular Diseases; Endothelial Cells; Inf | 2022 |
[Nutraceuticals (monacolin K, berberine and coenzyme Q10) in patients with moderate hypercholesterolemia and low-moderate cardiovascular risk. Potential benefits of combined therapies].
Topics: Berberine; Cardiovascular Diseases; Dietary Supplements; Heart Disease Risk Factors; Humans; Hyperch | 2023 |
The Berberis vulgaris L. extract berberine exerts its anti-oxidant effects to ameliorate cholesterol overloading-induced cell apoptosis in the primary mice hepatocytes: an in vitro study.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Berberis; Cardiovascular Diseases; Cholesterol; Hepatoc | 2022 |
The Berberis vulgaris L. extract berberine exerts its anti-oxidant effects to ameliorate cholesterol overloading-induced cell apoptosis in the primary mice hepatocytes: an in vitro study.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Berberis; Cardiovascular Diseases; Cholesterol; Hepatoc | 2022 |
The Berberis vulgaris L. extract berberine exerts its anti-oxidant effects to ameliorate cholesterol overloading-induced cell apoptosis in the primary mice hepatocytes: an in vitro study.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Berberis; Cardiovascular Diseases; Cholesterol; Hepatoc | 2022 |
The Berberis vulgaris L. extract berberine exerts its anti-oxidant effects to ameliorate cholesterol overloading-induced cell apoptosis in the primary mice hepatocytes: an in vitro study.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Berberis; Cardiovascular Diseases; Cholesterol; Hepatoc | 2022 |
Effect of berberine on cardiovascular disease risk factors: abridged secondary publication.
Topics: Berberine; Cardiovascular Diseases; Humans | 2023 |
Jatrorrhizine inhibits Piezo1 activation and reduces vascular inflammation in endothelial cells.
Topics: Animals; Berberine; Cardiovascular Diseases; Endothelial Cells; Hydrogen Peroxide; Ion Channels; Mic | 2023 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals.
Topics: Animals; Antineoplastic Agents; Berberine; Cardiovascular Diseases; Curcumin; Dietary Supplements; H | 2018 |
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.
Topics: Animals; Berberine; Caco-2 Cells; Cardiovascular Diseases; Dyslipidemias; Hep G2 Cells; Humans; Hypo | 2019 |
The protective effects of Berberine and Hesperidin on inflammatory factor-stimulating cardiac fibroblasts.
Topics: Animals; Animals, Newborn; Berberine; Cardiotonic Agents; Cardiovascular Diseases; Cell Differentiat | 2019 |
Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications.
Topics: Animals; Anti-Inflammatory Agents; Antidiarrheals; Antineoplastic Agents; Berberine; Berberis; Cardi | 2014 |
Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo.
Topics: Animals; Berberine; Blood Glucose; Cardiovascular Diseases; Cricetinae; Diabetes Mellitus, Experimen | 2015 |
Berberine via suppression of transient receptor potential vanilloid 4 channel improves vascular stiffness in mice.
Topics: Aging; Animals; Berberine; Blood Pressure; Cardiovascular Diseases; Hypertension; Mice; Organ Cultur | 2015 |
Anti-inflammatory treatment in patients after percutaneous coronary intervention: another potential use for berberine?
Topics: Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Cardiovascular D | 2012 |